Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDF NASDAQ:DTIL NASDAQ:GOSS NASDAQ:TERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDFCardiff Oncology$2.39-0.8%$3.52$2.09▼$5.64$160.33M1.543.19 million shs1.23 million shsDTILPrecision BioSciences$4.38-4.2%$4.73$3.61▼$11.09$50.67M1.52210,494 shs87,285 shsGOSSGossamer Bio$1.76+1.1%$1.51$0.66▼$2.23$395.64M1.963.50 million shs3.07 million shsTERNTerns Pharmaceuticals$6.08+7.8%$4.69$1.87▼$11.40$493.56M-0.051.06 million shs798,851 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDFCardiff Oncology-0.83%-9.47%-41.42%-10.15%+11.68%DTILPrecision BioSciences-4.16%-5.19%-7.40%-15.12%-49.01%GOSSGossamer Bio+1.15%-12.00%+29.41%+58.56%+116.72%TERNTerns Pharmaceuticals+7.80%+11.15%+24.34%+100.00%-8.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDFCardiff Oncology1.9505 of 5 stars3.40.00.00.03.21.70.6DTILPrecision BioSciences4.2435 of 5 stars3.53.00.04.61.41.71.3GOSSGossamer Bio3.9021 of 5 stars3.51.00.04.73.71.70.0TERNTerns Pharmaceuticals4.0459 of 5 stars3.32.00.04.13.13.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDFCardiff Oncology 2.83Moderate Buy$10.10322.59% UpsideDTILPrecision BioSciences 3.00Buy$47.00973.06% UpsideGOSSGossamer Bio 3.00Buy$8.50382.95% UpsideTERNTerns Pharmaceuticals 2.60Moderate Buy$15.63156.99% UpsideCurrent Analyst Ratings BreakdownLatest DTIL, TERN, CRDF, and GOSS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/6/2025CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $10.008/6/2025GOSSGossamer BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$4.00 ➝ $5.007/14/2025GOSSGossamer BioScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$11.007/8/2025CRDFCardiff OncologyLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.006/24/2025CRDFCardiff OncologyJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$3.506/18/2025CRDFCardiff OncologyWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/21/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.005/16/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.005/16/2025GOSSGossamer BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.005/13/2025TERNTerns PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$26.00 ➝ $15.005/9/2025CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.00(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDFCardiff Oncology$680K233.83N/AN/A$0.88 per share2.72DTILPrecision BioSciences$68.70M0.71N/AN/A$6.87 per share0.64GOSSGossamer Bio$114.70M3.49N/AN/A($0.20) per share-8.80TERNTerns PharmaceuticalsN/AN/AN/AN/A$3.49 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDFCardiff Oncology-$45.43M-$0.87N/AN/AN/A-9,344.14%-77.94%-63.65%8/14/2025 (Estimated)DTILPrecision BioSciences$7.17M-$2.01N/AN/AN/A-6,205.79%-158.77%-65.42%N/AGOSSGossamer Bio-$56.53M-$0.62N/AN/AN/A-344.81%-1,774.72%-46.73%8/11/2025 (Estimated)TERNTerns Pharmaceuticals-$88.85M-$1.04N/AN/AN/AN/A-27.35%-26.18%N/ALatest DTIL, TERN, CRDF, and GOSS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CRDFCardiff Oncology-$0.19N/AN/AN/A$0.10 millionN/A8/7/2025Q2 2025DTILPrecision BioSciences-$0.09-$2.13-$2.04-$2.13$6.27 million$0.02 million8/5/2025Q2 2025GOSSGossamer Bio-$0.18-$0.17+$0.01-$0.17$4.12 million$11.49 million8/5/2025Q2 2025TERNTerns Pharmaceuticals-$0.28-$0.26+$0.02-$0.26N/AN/A7/29/2025Q2 2025CRDFCardiff Oncology-$0.19-$0.21-$0.02-$0.21$0.11 million$0.12 million5/15/2025Q1 2025DTILPrecision BioSciences-$0.43-$2.21-$1.78-$2.21$5.00 million$0.03 million5/15/2025Q1 2025GOSSGossamer Bio-$0.18-$0.16+$0.02-$0.16$3.95 million$9.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDFCardiff OncologyN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDFCardiff OncologyN/A4.424.42DTILPrecision BioSciences0.456.626.62GOSSGossamer Bio6.704.405.71TERNTerns PharmaceuticalsN/A24.7030.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDFCardiff Oncology16.29%DTILPrecision BioSciences37.99%GOSSGossamer Bio81.23%TERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipCRDFCardiff Oncology7.70%DTILPrecision BioSciences4.50%GOSSGossamer Bio6.70%TERNTerns Pharmaceuticals1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDFCardiff Oncology2066.53 million61.40 millionOptionableDTILPrecision BioSciences20011.09 million10.59 millionNo DataGOSSGossamer Bio180227.38 million212.07 millionOptionableTERNTerns Pharmaceuticals4087.51 million86.20 millionNot OptionableDTIL, TERN, CRDF, and GOSS HeadlinesRecent News About These CompaniesTerns Pharmaceuticals (NASDAQ:TERN) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPSAugust 6 at 5:37 PM | marketbeat.comTerns Seeks Partners for Metabolic Assets Amid Oversaturated Obesity MarketAugust 6 at 4:36 PM | biospace.comBTerns to stop funding metabolic disease trials beyond 2025, seeks partners for assetsAugust 6 at 6:37 AM | fiercebiotech.comFTerns (TERN) Q2 Net Loss Narrows 16%August 6 at 2:52 AM | fool.comBrokerages Set Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Target Price at $15.63August 6 at 2:39 AM | americanbankingnews.comTerns Pharmaceuticals Reports Q2 2025 Financial ResultsAugust 6 at 2:49 AM | tipranks.comTerns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 5, 2025 | globenewswire.comTerns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)August 4, 2025 | globenewswire.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAugust 3, 2025 | marketbeat.comTerns Pharmaceuticals (TERN) to Release Earnings on MondayAugust 3, 2025 | americanbankingnews.comTerns Pharmaceuticals (TERN) to Release Quarterly Earnings on MondayJuly 28, 2025 | marketbeat.comObesity in Focus: ADA Reveals R&D Priorities for Blockbusters-in-WaitingJuly 14, 2025 | biospace.comBTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJuly 9, 2025 | marketbeat.comTerns Pharmaceuticals CEO & Director Acquires 98% More StockJuly 4, 2025 | finance.yahoo.comTerns pharmaceuticals CEO Burroughs buys $90k in sharesJune 27, 2025 | investing.comRivus' weight loss drug scores MASH phase 2 win, showcases muscle-sparing potentialJune 26, 2025 | fiercebiotech.comFTerns Pharmaceuticals Presents Promising Phase 1 Data for TERN-601 at ADA 2025 and Completes Enrollment for Phase 2 FALCON Trial - NasdaqJune 24, 2025 | nasdaq.comTerns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American ... - MorningstarJune 24, 2025 | morningstar.comMNovel GLP-1/GIP Agent Led to Weight Loss With Once-Monthly DosingJune 23, 2025 | medpagetoday.comMTerns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific SessionsJune 23, 2025 | globenewswire.comPopulation-Level Weight Loss Seen With Primary Care ProtocolJune 21, 2025 | medscape.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBigBear.ai: Why a 90% Rally Could Be Just the StartBy Jeffrey Neal Johnson | July 10, 2025View BigBear.ai: Why a 90% Rally Could Be Just the StartRigetti Soars 30% on Latest Quantum Leap: What It Means Long-TermBy Leo Miller | July 22, 2025View Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-TermCSX Stock Rally: Strong Options Flow, Analyst Price TargetsBy Jeffrey Neal Johnson | July 18, 2025View CSX Stock Rally: Strong Options Flow, Analyst Price TargetsWhy Freeport-McMoRan Stock May Hit a New High After Earnings BeatBy Chris Markoch | July 25, 2025View Why Freeport-McMoRan Stock May Hit a New High After Earnings BeatGlobal Value: 3 Stocks Under $10 Riding a Weak DollarBy Chris Markoch | July 30, 2025View Global Value: 3 Stocks Under $10 Riding a Weak DollarDTIL, TERN, CRDF, and GOSS Company DescriptionsCardiff Oncology NASDAQ:CRDF$2.39 -0.02 (-0.83%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.42 +0.02 (+1.05%) As of 08/8/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Precision BioSciences NASDAQ:DTIL$4.38 -0.19 (-4.16%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$4.33 -0.05 (-1.23%) As of 08/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Gossamer Bio NASDAQ:GOSS$1.76 +0.02 (+1.15%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.79 +0.03 (+1.70%) As of 08/8/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Terns Pharmaceuticals NASDAQ:TERN$6.08 +0.44 (+7.80%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$6.09 +0.01 (+0.16%) As of 08/8/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
